Sprout Group on Wednesday named James Niedel as venture partner for healthcare technology investments.

Previously, Neidel served as chief science and technology officer for U.K.-based pharmaceutical giant GlaxoSmithKline (GSK). GSK has its joint U.S. headquarters in Research Triangle Park and Philadelphia.

While at Glaxo, Neidel’s responsibilities included global research and development, information technology and product strategy. Prior to his stint at Glaxo, Neidel, a Searle Scholar, served as professor of medicine and chief of the division of clinical pharmacology at Duke Medical School.

Neidel quit GSK last summer.

Currently an affiliate of Credit Suisse First Boston, the Sprout Group was founded in 1969 and maintains offices in Menlo Park, CA, New York and Chicago. It has anaged 12 major investment partnerships totaling over $3 billion in committed capital.

The most recent investment partnership is Sprout Capital IX, a $1.6 billion fund that makes early stage, growth, mezzanine, and buyout investments primarily in the industries of datacom and telecom, healthcare technology, software and technology. Historically, Sprout has also made selective investments in the e-commerce and services sectors.

Sprout Group: www.sproutgroup.com